Literature DB >> 19194011

Expression, purification, crystallization and preliminary X-ray studies of the Ebola VP35 interferon inhibitory domain.

Daisy W Leung1, Nathaniel D Ginder, Jay C Nix, Christopher F Basler, Richard B Honzatko, Gaya K Amarasinghe.   

Abstract

Ebola VP35 is a multifunctional protein that is important for host immune suppression and pathogenesis. VP35 contains an N-terminal oligomerization domain and a C-terminal interferon inhibitory domain (IID). Mutations within the VP35 IID result in loss of host immune suppression. Here, efforts to crystallize recombinantly overexpressed VP35 IID that was purified from Escherichia coli are described. Native and selenomethionine-labeled crystals belonging to the orthorhombic space group P2(1)2(1)2(1) were obtained by the hanging-drop vapor-diffusion method and diffraction data were collected at the ALS synchrotron.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19194011      PMCID: PMC2635856          DOI: 10.1107/S1744309108044187

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  16 in total

1.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.

Authors:  Amy L Hartman; Jonathan S Towner; Stuart T Nichol
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

2.  Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription.

Authors:  Peggy Möller; Nonia Pariente; Hans-Dieter Klenk; Stephan Becker
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR.

Authors:  Zongdi Feng; Melissa Cerveny; Zhipeng Yan; Bin He
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

4.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

5.  Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.

Authors:  Amy L Hartman; Jason E Dover; Jonathan S Towner; Stuart T Nichol
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein.

Authors:  St Patrick Reid; Washington B Cárdenas; Christopher F Basler
Journal:  Virology       Date:  2005-08-10       Impact factor: 3.616

7.  VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice.

Authors:  Sven Enterlein; Kelly L Warfield; Dana L Swenson; David A Stein; Jeffery L Smith; C Scott Gamble; Andrew D Kroeker; Patrick L Iversen; Sina Bavari; Elke Mühlberger
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

8.  Structure of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; D Bruce Fulton; Jay Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

9.  Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus.

Authors:  Amy L Hartman; Brian H Bird; Jonathan S Towner; Zoi-Anna Antoniadou; Sherif R Zaki; Stuart T Nichol
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

10.  The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.

Authors:  Christopher F Basler; Andrea Mikulasova; Luis Martinez-Sobrido; Jason Paragas; Elke Mühlberger; Mike Bray; Hans-Dieter Klenk; Peter Palese; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  8 in total

1.  Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function.

Authors:  Kathleen C Prins; Jennifer M Binning; Reed S Shabman; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  Crystallization and preliminary X-ray analysis of Ebola VP35 interferon inhibitory domain mutant proteins.

Authors:  Daisy W Leung; Dominika Borek; Mina Farahbakhsh; Parameshwaran Ramanan; Jay C Nix; Tianjiao Wang; Kathleen C Prins; Zbyszek Otwinowski; Richard B Honzatko; Luke A Helgeson; Christopher F Basler; Gaya K Amarasinghe
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-05-27

3.  Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Reed S Shabman; Mina Farahbakhsh; Kathleen C Prins; Dominika M Borek; Tianjiao Wang; Elke Mühlberger; Christopher F Basler; Gaya K Amarasinghe
Journal:  J Mol Biol       Date:  2010-04-24       Impact factor: 5.469

4.  Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35.

Authors:  Daisy W Leung; Kathleen C Prins; Dominika M Borek; Mina Farahbakhsh; JoAnn M Tufariello; Parameshwaran Ramanan; Jay C Nix; Luke A Helgeson; Zbyszek Otwinowski; Richard B Honzatko; Christopher F Basler; Gaya K Amarasinghe
Journal:  Nat Struct Mol Biol       Date:  2010-01-17       Impact factor: 15.369

5.  Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs.

Authors:  Kathleen C Prins; Sebastien Delpeut; Daisy W Leung; Olivier Reynard; Valentina A Volchkova; St Patrick Reid; Parameshwaran Ramanan; Washington B Cárdenas; Gaya K Amarasinghe; Viktor E Volchkov; Christopher F Basler
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

6.  Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism.

Authors:  Shridhar Bale; Jean-Philippe Julien; Zachary A Bornholdt; Christopher R Kimberlin; Peter Halfmann; Michelle A Zandonatti; John Kunert; Gerard J A Kroon; Yoshihiro Kawaoka; Ian J MacRae; Ian A Wilson; Erica Ollmann Saphire
Journal:  PLoS Pathog       Date:  2012-09-13       Impact factor: 6.823

7.  The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing.

Authors:  Kari A Dilley; Alexander A Voorhies; Priya Luthra; Vinita Puri; Timothy B Stockwell; Hernan Lorenzi; Christopher F Basler; Reed S Shabman
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

8.  A cryptic pocket in Ebola VP35 allosterically controls RNA binding.

Authors:  Matthew A Cruz; Thomas E Frederick; Upasana L Mallimadugula; Sukrit Singh; Neha Vithani; Maxwell I Zimmerman; Justin R Porter; Katelyn E Moeder; Gaya K Amarasinghe; Gregory R Bowman
Journal:  Nat Commun       Date:  2022-04-27       Impact factor: 17.694

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.